



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Leo Mascarenhas, M.D.

Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 17-18, 2020

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: information will be presented regarding pediatric development plans for four products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of Written Requests for pediatric studies, if appropriate. The products under consideration, relevant to the waiver, are: On June 17th, SP 2577, application presentation by Salarius Pharmaceuticals, Inc.; and, marizomib, application presentation by Celgene International II Sàrl, a wholly owned subsidiary of Bristol-Myers Squibb; and on June 18th, CD30.CART, application presentation by Tessa Therapeutics, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
none		
II. Other Imputed Interests		
contract/grant	Salarius, party to the matter	(b) (4) per year
contract/grant	Astra Zeneca, potentially competing firm	\$ (b) (4) – \$ (b) (4) total

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/
Signature

5/28/20
Date